Home › Cancer (all types) › NCT06116032

Immune Profiling for Cancer Immunotherapy Response

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Cancer patients receiving or will receive immunotherapy under FDA- approved indication (e.g. checkpoint inhibitor therapy with pembrolizumab, nivolumab, or ipilimumab, or cellular immunotherapy).
* Participants are eligible regardless of the type of prior therapy (i.e. prior immunotherapy treated participants can be included).

Exclusion Criteria:

* Pregnant women/fetuses/neonates
* Prisoners
* Decision-impaired individuals

About the study

In patients clinically treated with FDA-approved immunotherapy the investigators will assess the predictive value of pre- and on-treatment 1) immune-methylation profiling across cancer types, and 2) immune-methylation profiling and cytokine profiling within cancer types.

What is being tested

• Methylation Cytometry (diagnostic test)

Sponsor: Dartmouth-Hitchcock Medical Center · Participants: 1,500 · Started: Oct 3, 2022

Contact the study team

• Brock C Christensen, PhD · Phone: 603-650-1827
• Hannah G Stolrow, BA · Phone: 7205174950

Official record on ClinicalTrials.gov — NCT06116032

Locations in the U.S.

Conditions

• Cancer (all types)
• Blood Cancers

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.